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The innate defense system of the female mucosal genital tract involves a close and 
complex interaction among the healthy vaginal microbiota, different cells, and various 
proteins that protect the host from pathogens. Vaginal lactobacilli and lactoferrin represent 
two essential actors in the vaginal environment. Lactobacilli represent the dominant bac-
terial species able to prevent facultative and obligate anaerobes outnumber in vaginal 
microbiota maintaining healthy microbial homeostasis. Several mechanisms underlie the 
protection exerted by lactobacilli: competition for nutrients and tissue adherence, reduc-
tion of the vaginal pH, modulation of immunity, and production of bioactive compounds. 
Among bioactive factors of cervicovaginal mucosa, lactoferrin, an iron-binding cationic 
glycoprotein, is a multifunctional glycoprotein with antibacterial, antifungal, antiviral, and 
antiparasitic activities, recently emerging as an important modulator of inflammation. 
Lactobacilli and lactoferrin are largely under the influence of female hormones and of 
paracrine production of various cytokines. Lactoferrin is strongly increased in lower gen-
ital tract mucosal fluid of women affected by Neisseria gonorrheae, Chlamydia tracho-
matis, and Trichomonas vaginalis infections promoting both innate and adaptive immune 
responses. In vaginal dysbiosis characterized by low amounts of vaginal lactobacilli and 
increased levels of endogenous anaerobic bacteria, the increase in lactoferrin could act 
as an immune modulator assuming the role normally played by the healthy microbiota 
in vaginal mucosa. Then lactoferrin and lactobacilli may be considered as biomarkers 
of altered microbial homeostasis at vaginal level. Considering the shortage of effective 
treatments to counteract recurrent and/or antibiotic-resistant bacterial infections, the 
intravaginal administration of lactobacilli and lactoferrin could be a novel efficient thera-
peutic strategy and a valuable tool to restore mucosal immune homeostasis.
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iNTRODUCTiON
The basic structures of the female reproductive system are ovaries, Fallopian tubes, uterus, cervix, 
and vagina. Ovaries are responsible for the production of the ovum and secrete both estrogen and 
progesterone. When an ovum is developing in an ovary, it is encapsulated in a sac known as an 
ovarian follicle. On maturity of the ovum, the follicle and the ovary’s wall rupture, allowing the ovum 
to escape and enter the fallopian tube to reach uterus. The uterus is a muscular organ useful to accept 
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a fertilized ovum, which becomes implanted into the endometrium. 
The cervix is the neck of the uterus, which protrudes through the 
upper anterior vaginal wall. The vagina is a fibromuscular canal 
that connects the upper part of female genital tract to the outside 
of the body and represents the portal of entry of pathogenic 
microorganisms. The epithelial mucosa of the lower genital tract 
is extensively colonized by commensal microorganisms, while the 
tissues of the upper genital tract are generally considered to be ster-
ile (1). However, bacterial colonization of the upper genital tract of 
healthy asymptomatic women remains a somehow controversial 
issue (1).
The vaginal tract is colonized by microorganisms, recognized 
as the vaginal microbiota (VM). These microorganisms, in 
addition to a complex synergism among secretion’s proteins and 
peptides, epithelial, and immune cells, perform a pivotal role in 
the defense of female genital tract against infectious and inflam-
matory processes.
In the state of mucosal health, the various components are in 
balance. The rupture of mucosal homeostasis determined by the 
alteration of one of the various actors often results in an increased 
host susceptibility to infections. Healthy VM is dominated by 
Lactobacillus spp., but other microorganisms can be present at 
lesser extent (Gardnerella, Prevotella, Streptococcus, Ureaplasma, 
Peptostreptococcus, Staphylococcus, Corynebacterium, Clostridium, 
Mycoplasma, Enterococcus, Bacteroides, Escherichia, Bifidobac­
terium, Veillonella, and Candida) (2–6).
Over 20 species of Lactobacillus have been detected in the 
vagina. However, in the majority of women, the healthy vaginal 
microflora contains one or two Lactobacillus species among 
Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jense­
nii, and Lactobacillus iners (7, 8). Currently, the role of L. iners in 
vaginal health is still unclear (9). Indeed, L. iners has been recently 
detected in both dysbiotic and healthy women, and its presence 
and amount are inversely correlated with L. crispatus (8, 10, 11).
Lactobacilli are involved in maintaining the healthy vaginal 
environment by counteracting overgrowth of other resident 
microorganisms (12). Lactobacilli can also colonize the human 
cervix. In different studies, a range of 29–52% of women resulted 
colonized by lactobacilli in the cervix, and within a single subject, 
usually the same Lactobacillus strains colonized both the cervix 
and the vaginal tract (13–15). Lactobacilli exert their protective 
effects by several mechanisms: (i) microbial competition for the 
nutrients and for adherence to the vaginal epithelium; (ii) reduc-
tion of the vaginal pH by the production of organic acids, espe-
cially lactic acid, through the degradation of glycogen released by 
vaginal cells thus exerting selective antimicrobial activity against 
non-resident microbiota; (iii) production of antimicrobial sub-
stances, such as bacteriocins and hydrogen peroxide (H2O2) able 
to suppress the growth of several microorganisms; and (iv) modu- 
lation of the local immune system (16). Homeostasis of vaginal 
environment results from complex interactions and synergies 
among the host and different microorganisms that colonize the 
vaginal mucosa, and the maintenance of high numbers of resident 
lactobacilli is an effective hallmark of woman’s health and a well- 
organized protection against pathogens causing sexually tranmit-
ted infections (STIs). Abnormal VM involving a strong reduction or 
disappearance of lactobacilli characterizes a pathologic condition 
known as bacterial vaginosis (BV) that afflicts fertile, premeno-
pausal, and pregnant women with an incidence rate ranging from 
20 to 50% (17). BV is a polymicrobial clinical syndrome result-
ing from the replacement of the normal Lactobacillus spp. with 
high number of anaerobic bacteria such as Gardnerella vaginalis, 
Prevotella spp., Mobiluncus spp., Ureaplasma, Mycoplasma, and 
other fastidious or not culturable anaerobes (5, 18). In BV, the 
overgrowing anaerobes produce compounds such as polyamines 
and other molecules capable of inducing the release of pro-
inflammatory cytokines such as IL-1β, IL-6, and IL-8 (19, 20). 
BV represents an independent risk factor for severe reproductive 
tract sequelae associated with pelvic inflammatory disease and 
tubal factor infertility (21, 22). Changes in the VM have been also 
associated with obstetrical complications such as late miscarriage 
and premature birth (23), thus exerting a profound impact also 
on the health of newborns. Moreover, women with Lactobacillus 
poor flora show an increased susceptibility to sexually transmit-
ted pathogens. Several studies indicate that abnormal VM lacking 
lactobacilli is associated with the acquisition of infections by 
Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas 
vaginalis (24–28).
Furthermore, the alterations in VM are associated with in- 
creased risk of acquiring viral sexually transmitted diseases 
(STDs). Indeed, longitudinal and cross-sectional studies dem-
onstrated the association between altered VM and the increased 
prevalence/incidence of many viral STIs such as human immu-
nodeficiency virus (HIV), herpes simplex virus (HSV), human 
papillomavirus, and cytomegalovirus infection (29).
In addition to lactobacilli, the cervicovaginal fluid (CVF) 
exerts a significant microbicidal activity against Gram-positive 
and Gram-negative bacteria, fungi, and certain viruses as well 
as an anti-inflammatory activity through several peptides and 
proteins, all characterized by common cationic features (30). 
The main antimicrobial peptides and proteins present in the CVF 
are shown in Table  1 (31–46). These peptides and proteins 
act through different mechanisms: (i) microbial lysis; (ii) depletion 
of environmental nutrients essential for microbial growth; 
(iii) competitive binding to host cells; (iv) degradation of negatively 
charged microbial surface components; (v) interference with host 
cell signaling pathways; and (vi) modulation of inflammation and 
other functions involved in host defense (34, 47). The bactericidal 
activity of many of these compounds is strictly associated with 
their cationic features. The concentration of some of these mol-
ecules in CVF is lower than that required for in vitro inhibition of 
pathogens; however, it is known that several antimicrobials display 
synergistic effects. Indeed, human β defensin 2 and cathelicidin 
antimicrobial peptide LL-37 (48), secretory leukocyte protease 
inhibitor (SLPI) and lysozyme (49), and lactoferrin (Lf) and 
lysozyme (49) display synergistic effects that potentially increase 
innate immune protection in the female reproductive tract (50).
Many of these antimicrobial/immunomodulatory compounds 
appear to be under hormonal control (31). In CVF α and β de-
fensins, SLPI and lysozyme levels are high during the proliferative 
phase, greatly decrease at mid-cycle/ovulation, and increase again 
during the late secretory phase.
Lactoferrin, belonging to transferrin family, is a multifunc-
tional glycoprotein of about 690 amino acids and a MW of 
TabLe 1 | Antimicrobial peptides/proteins of the female genital tract.
Peptide/protein Source antimicrobial effect Reference
SLPI Epithelial cells Gram-positive and Gram-
negative bacteria
(31, 32)
α-defensins Neutrophils Gram-positive and Gram-
negative bacteria
(31, 33–35)



























Lysozyme Macrophages Gram-positive bacteria (42, 43)
Monocytes HIV
Neutrophils HSV
Lactoferrin Epithelial cells Gram-positive and Gram-
negative bacteria
(44–46)
Neutrophils Enveloped and non-
enveloped viruses
HIV, human immunodeficiency virus; HSV, herpes simplex virus; SLPI, secretory 
leukocyte protease inhibitor.
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80 kDa. Lf chelates two Fe (III) per molecule with high affinity 
(Kd ~ 10–20 M) until very low pH as 3.0, characteristic of infection 
sites (44, 51, 52). Lf, abundantly found in most biological fluids 
of mammals, is synthesized by exocrine glands, many mucosal 
epithelial cells and released by neutrophils during inflammation. 
The highest level of the human Lf (hLf) is found in colostrum 
(7 mg/ml), while decreases in mature milk (1.5–4.0 mg/ml). In 
the tears, hLf is detected at low concentration (about 2.0 mg/ml), 
while in saliva, small intestine, earwax, vaginal fluid, amniotic 
fluid, upper airway fluid, seminal plasma, and the cervical 
mucus at very low levels (<0.1  mg/ml) (53). In particular, the 
concentration of hLf in human vaginal fluid corresponds to 
1–3 µg/ml, while it is extremely high (100 µg/ml) in the cervi-
cal mucus plug (30, 54, 55). Of note, a total number of 106 
neutrophils release 15  µg of hLf in sites of inflammation and 
infection (53).
In human body fluids, the concentration of free available iron 
must not overcome 10–18  M to avoid microbial multiplication 
and to hinder the precipitation of insoluble ferric hydroxides 
as well as the formation of reactive oxygen species. HLf, by its 
iron-binding ability, guarantees that free available iron does not 
exceed 10–18 M. HLf and bovine milk derivative Lf (bLf) possess 
high homology of sequence. From three-dimensional structure, 
Lf is folded into two homologous lobes, each structured in two 
domains (N1 and N2, C1 and C2). One Fe (III) ion is chelated by 
each lobe. When Lf is completely iron saturated, its conformation 
appears in a closed state, more resistant to proteolytic enzymes 
than the unsaturated open form (51). The low iron availability 
(10–18 M), hindering microbial growth, is a signal of health and 
wellness, while iron concentration higher than 10–18 M favors not 
only microbial replication but also the biofilm formation (56, 57) 
and persistence (44).
Interestingly, Wiesner and Vilcinskas have reported that pro-
teins and peptides of mucosal secretions possess several functions 
(58). Accordingly, hLf and bLf are multifunctional glycoproteins 
effective against bacteria, mycetes, viruses, and parasites, possess-
ing also anti-inflammatory and immunomodulatory properties 
(44). In particular, bLf, available in large quantities and recog-
nized by Food and Drug Administration (FDA, USA) as a safe 
substance, is the main Lf used in in vitro studies (44) as well as in 
clinical trials (52, 59–62) and in mice (63).
The level of vaginal hLf and others antimicrobial peptides 
change in response to microbial infections. It has been demon-
strated that hLf and defensin levels increase in genital secretion 
of women with C. trachomatis, N. gonorrhoeae, T. vaginalis, or 
Candida spp. infection and BV in comparison to healthy con-
dition (64, 65).
aNTiMiCRObiaL aCTiviTY OF 
LaCTObaCiLLi aND Lf
Lactobacilli
The innate defense system of the female mucosal genital tract 
involves a complex interaction among the healthy vaginal flora, 
immune cells, and several proteins that defend the host from 
pathogens. It is broadly suggested that the crucial role of vaginal 
lactobacilli is to protect female genital tract through the produc-
tion of lactic acid responsible for low vaginal pH that inhibits 
sexually transmitted pathogens. Lactic acid is in equilibrium with 
lactate anion. The former is the predominant form in healthy 
vaginal conditions and low pH (<4.5), thus exerting antimicro-
bial activity against pathogens. Lactate anion predominates at 
higher pH (>4.5) conditions in women with dysbiosis (66). 
In vitro experiments demonstrated that at physiological concen-
trations (55–111 mM) of lactic acid and at pH 4.5, BV-associated 
bacteria such as G. vaginalis and Atopobium vaginae were inac-
tivated without effects on typical vaginal species of lactobacilli 
(67). Furthermore, inactivation of BV-associated species was 
dependent on lactic acid itself rather than pH, since a pH value of 
4.5 determined by other acids was significantly less microbicidal. 
Recent in vitro studies, however, demonstrated that C. trachomatis 
multiplication is inhibited by different strains of vaginal lactoba-
cilli, independently from pH alterations (68). C. trachomatis, an 
obligate intracellular pathogen, responsible for the most common 
bacterial STD worldwide, causes acute and chronic infections. 
Unlike acute infections, which can be cured with oral or topical 
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administration of antibiotics, chronic infections are difficult to 
eradicate and need prolonged therapies, thus increasing the risk 
of developing antibiotic resistance (69). Therefore, novel alterna-
tive therapies are needed. The difficulty in finding new agents 
against C. trachomatis infection resides in the complex life cycle 
of this peculiar pathogen. In fact, C. trachomatis has a unique 
biphasic developmental cycle, alternating between the extracel-
lular infectious elementary bodies (EBs), metabolically inactive, 
and the intracellular non-infectious reticular bodies (RBs), which 
are metabolically active. It has been recently demonstrated that 
vaginal lactobacilli inhibit EBs adhesion to epithelial cells as well 
as the intracellular RBs replication (68). The effect on the early 
phases of infection was related both to co-aggregation between 
lactobacilli and C. trachomatis and to competition for epithelial 
cell adhesion. The inhibition of chlamydial infection by lactoba-
cilli was strain and dose dependent, suggesting that the strains 
and the amount of lactobacilli in the vagina are responsible for 
the protection from chlamydial infection.
Lactobacilli have been demonstrated to protect lower female 
genital tract also from N. gonorrhoeae infection, the second most 
common bacterial STI. The interaction between bacteria and host 
cells determines the success of the pathogen mucosal coloniza-
tion or its elimination through the continuous fluid flow. In this 
respect, Vielfort et al. (15) showed that lactobacilli compete with 
N. gonorrhoeae for adhesion to human cervical cells. It has been 
also demonstrated that L. jensenii ATCC 25258 could reduce 
both adhesion and invasion of N. gonorrhoeae, whereas L. gasseri 
ATCC 33323 could displace adherent gonococci from the cell 
surface (70).
The protection exerted by healthy VM toward viral infections 
can be ascribed to a direct virucidal effect or to the maintenance 
of natural defense factors present in the vaginal milieu. Some 
mechanisms have been suggested by results obtained from both 
in vitro experiments and clinical observations in infected women 
(29). Lactobacillus metabolites possessing antimicrobial activity 
may be directly protective against viral infections.
Hydrogen peroxide (H2O2) produced by lactobacilli plays an 
important role as a natural microbicide within the vaginal ecosys-
tem due to its toxic activity against a number of microorganims 
and viruses, including HIV-1 (71) and HSV-2 (72). It has been 
observed that a range of 70–95% of lactobacilli present in the 
vaginal flora of healthy women produce H2O2. This percentage 
drops to 5% in women affected by vaginal infections (73).
The physiological acid vaginal pH value (≤4.5) determined 
by lactobacilli inactivates HIV (74) and HSV-2 (75). In addition, 
HSV-2 is inactivated by lactic acid concentrations leading to pH 
values similar to the ones detected in the healthy human vagina 
(72). Several compounds released from lactobacilli can impair the 
efficiency of target cells in supporting viral replication. A non- 
protein cell wall component extracted from a vaginal strain of 
Lactobacillus brevis strongly reduces HSV-2 replication in cell 
culture (76), whereas acid Lactobacillus metabolic products 
decrease activation of T  lymphocytes, with a consequent lower 
lymphocyte susceptibility to HIV-1 infection (77).
A healthy VM contributes to the maintenance of the natural 
defense mechanisms from invading pathogens. The gel layer 
coat of the vaginal and cervical mucosa represents a physical 
barrier that hinders viral binding to cell membrane receptors, thus 
protecting women from viral infections. Indeed, in vitro studies 
demonstrated that HSV could be trapped into the viscous cervi-
cal mucus (78). BV-related microorganisms are able to produce 
higher levels of mucin-degrading enzymes, such as mucinase 
and sialidase, in comparison to lactobacilli-dominated healthy 
vaginal flora (79–81). Therefore, an increased degradation of the 
protective mucus layer may promote binding of HSV-2 and other 
viruses to the underlying epithelial cell receptors. Further studies 
have demonstrated that vaginal lactobacilli are able to inhibit the 
first steps of HSV-2 infection in cell culture (72, 76). The antiviral 
activity exerted by the presence of lactobacilli during HSV-2 bind-
ing to the cell membrane is strain dependent and appears directly 
related to the adhesion capacity of Lactobacillus strains (82).
In conclusion, several mechanisms may be involved in the 
antimicrobial effect of vaginal lactobacilli: interference with 
microorganisms in the process of adhesion or entry into host 
cells, production of metabolites with a direct antimicrobial effect, 
production of compounds able to inhibit obligate intracellular 
pathogen replication, and contribution to the maintenance of 
natural defense factors present in the vaginal milieu.
Lactoferrin
As already discussed, hLf is one of the most important defense 
proteins of CVF. In fact, endogenous hLf has been found increased 
in the genital fluid of women affected by Neisseria gonorrheae, 
C. trachomatis, and T. vaginalis infections and/or vaginal dysbiosis 
(64). In this respect, hLf released by neutrophils recruited in situ 
could represent a marker of non-healthy conditions and one 
of the mediators involved in counteracting the inflammatory 
mileu.
The first function of hLf, recognized in  vitro, was the bac-
teriostatic activity depending on its ability to sequester iron 
necessary for bacterial survival and growth (83). HLf and bLf 
establish a battle for iron acquisition with pathogens, capable to 
counteract these iron-binding proteins by synthesizing sidero-
phores, small high affinity iron-chelating molecules, or through 
iron acquisition from other sources (65). As a matter of fact, 
G. vaginalis, lacking of siderophores, acquires iron by the lysis of 
erythrocytes, using hemoglobin as iron source. This is consistent 
with the observation that G. vaginalis level increases during 
menses (6).
Moreover, independently from iron-binding ability, bLf exerts 
several antibacterial activities: (i) bacterial lysis through its 
binding to lipopolysaccharide (LPS); (ii) inhibition of bacterial 
adhesion to the epithelial cells; and (iii) inhibition of the entry 
into host cells by facultative or obligate intracellular bacteria 
through competitive binding to host cells and/or to microbial 
surface components [(44) and references therein (46, 84)]. Of 
note, facultative intracellular pathogens require intracellular 
nutrients, including iron, for replication in mammalian cells, and 
obligate intracellular C. trachomatis is no exception (85).
A preparation of bLf, iron saturated at 20% to consent 
further iron chelation, was utilized in in vitro model to check 
its antichlamydial activity (84). Similar to that observed using 
vaginal lactobacilli, the incubation of cell monolayers with 
bLf before the infection or at the moment of the infection 
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significantly inhibited the adhesion and entry of C. trachomatis 
into epithelial cells. Therefore, the inhibition of C. trachomatis 
infectivity by bLf was dependent on its interaction with the cell 
surface and especially with glycosaminoglycans and heparan 
sulfate proteoglycans (86), which are potential receptors for 
C. trachomatis adhesion (87). Conversely, the preincubation of 
bLf with C. trachomatis EBs did not influence its infectivity, 
supporting the idea that the specific interaction between bLf 
and epithelial host cells could be the sole mechanism responsible 
for the inhibition of C. trachomatis invasion (84). Recently, the 
inhibition of IL-6 and IL-8 synthesis by bLf has been demon-
strated in in  vitro model, mimicking the in  vivo chlamydial 
infection. BLf, added to infected cells 3  h postinfection, pro-
duced a significant decrease of IL-6 and IL-8 without any effect 
on the number of intracellular Chlamydia. Similarly, IL-6 levels 
were reduced when bLf was added 3 h postinfection to epithelial 
monolayers infected with other facultative intracellular bacteria 
or to LPS-stimulated macrophages (88–90). The anti-chlamydial 
activity of bLf related to its anti-inflammatory function has been 
shown in vivo. In a pilot study, 7 of 176 pregnant women show-
ing cervical specimens positive for C. trachomatis were treated 
with the intravaginal administration of bLf (100 mg) every 8 h 
for 30  days. Interestingly, after 1  month, six women resulted 
negative for C. trachomatis and showed significant decreased 
IL-6 levels in their CVF (84). Similar to what observed in 
in vitro model, intravaginal administration of bLf seems to act 
by protecting mucosal host cells against the adhesion and entry 
of chlamydial EBs, which are released extracellularly after redif-
ferentiation of RBs to EBs. The decrease of IL-6 levels could be a 
marker for the inhibition of C. trachomatis EBs infection of host 
cells due to the presence of bLf. In other words, bLf protects host 
cells and prevents the early phase of infection by EBs. Unlike 
lactobacilli (68), bLf does not affect the replication of RBs (84). 
The potential influence of exogenous bLf on microbial commu-
nities populating vagina has been recently investigated. Vaginal 
bLf administration to 60 women with BV has been shown to 
be able to modify VM composition. In fact, the treatment 
induced a reduction of BV-associated Gardnerella, Prevotella, 
and Lachnospira genera as well as an increase of Lactobacillus 
species (91). These data suggest the therapeutic potential of 
bLf in counteracting female genital tract diseases. Indeed, it 
would be relevant to unveil the molecular mechanisms as well 
as the immunological changes accompanying bLf effects on 
microbiota.
Furthermore, bLf antiviral activity, verified against both 
enveloped and naked viruses, is exerted in the early stage of 
infection, thus inhibiting viral binding and entry into the host 
cell. This activity is mainly due to bLf binding to heparan sul-
fate glycosaminoglycan cell receptors or viral particles or both 
(45). Similar to viral particles, the inhibition of Plasmodium 
endocytosis is attributed to the interaction between bLf and 
both cell surface heparan sulfate and lipoprotein receptor-related 
protein (92–95).
In this respect, bLf represents the most relevant protein sym-
bolizing a brick in the wall of natural non-immune defenses of 
human mucosal fluids against microbial infections (44).
LaCTObaCiLLi aND Lf HOST iMMUNe 
SYSTeM MODULaTiON
Lactobacilli
It is well known that lactobacilli are endowed with health-
promoting and immunomodulatory properties. Along with bifi-
dobacteria, they have been proposed as candidates for prevention 
and/or treatment of allergy, colitis, infections, and other inflam-
matory conditions (96). Some Lactobacillus strains have been 
also proposed as vaginal microbicide candidates against STI 
(e.g., N. gonorrhoeae, Candida albicans, and HIV). Besides 
mechanisms related to the bacterium itself (e.g., enhancement 
of epithelial barrier function and competition with pathogens), 
the capability to redirect the immune response underlies many 
of the beneficial effects of lactobacilli. In vitro data demonstrate 
that L. crispatus (97–99) and L. jensenii (100) act not only through 
colonization of epithelial cells but also influencing the cytokine 
secretion pattern. In particular, upon recognition through Toll-
like receptor (TLR) 2/6 and 2/4, NF-κB signaling is activated 
without induction of pro-inflammatory mediators (IL-1β, IL-1α, 
and TNF-α). Furthermore, secretion of cytokines as IL-8 is 
inhibited, while production of IL-10, IL-6, and defensins can be 
induced ensuring homeostasis of immune responses. Although 
innate immunity is the first level to be influenced by the probiotic 
interaction with mucosal epithelium, other cells (e.g., dendritic 
cells) can be shaped by lactobacilli to skew adaptive responses. 
An example is represented by L. crispatus SJ-3C-US strain, which 
was shown to confer anti-inflammatory properties to dendritic 
cells by inducing upregulation of IL-10 production and induction 
of regulatory T cells (101). As mentioned above, a key metabolite 
produced by lactobacilli is lactic acid. Besides its antimicrobial 
properties, many of the immune modulation mechanisms exerted 
by lactobacilli can be ascribed to this compound. In particular, lac-
tic acid has been shown to induce an anti-inflammatory response 
from vaginal and cervical epithelial cells by inhibiting IL-6, IL-8, 
RANTES, and TNF-α secretion stimulated by TLR agonists used 
to mimic pathogen-associated molecular patterns (PAMPs) from 
microbes (102). Given that IL-6, IL-8, and TNF-α are known to 
promote replication of HIV through activation of NF-κB tran-
scription in HIV target cells, lactic acid produced by lactobacilli 
in the vaginal environment could be relevant in the context of 
viral infection acquisition. Furthermore, the anti-inflammatory 
cytokine IL-1RA was induced by lactic acid treatment of cer-
vicovaginal epithelial cells. All these anti-inflammatory effects 
were mediated by both l- and d-lactic acid isomers and by the 
protonated form which predominates in healthy conditions with 
low values of vaginal pH (102, 103). Very few data about the 
immunological changes associated with benefits induced by lac-
tobacilli administration are available in the vaginal tract in vivo 
in both physiological and pathological conditions. Lactobacillus 
salivarius CRL 1328 and L. gasseri CRL 1263 have been proposed 
as good candidates to keep a balanced microbiota and immune 
surveillance. Indeed, in a murine model set up to evaluate the 
benefits of lactobacilli and their effects on the mouse vaginal 
mucosa and innate immune cells, lactobacilli inoculation did not 
modify the amounts of granulocytes and macrophages in vaginal 
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washings (104). In humans, it has been shown that administration 
of probiotic Lactobacillus vaginal tablets produces a significant 
reduction in the levels of vaginal IL-1β and IL-6 cytokines dem-
onstrating the capacity of lactobacilli to modulate the production 
of inflammatory cytokines in both women with BV and women 
with healthy vaginal flora (105, 106).
A link between oral probiotic administration and VM/immune 
markers has been recently demonstrated by Vitali et al. on preg-
nant women (107). The authors investigated the effects of dietary 
supplementation with VSL#3 probiotic mixture containing eight 
species of Lactobacillus, Bifidobacterium, and Streptococcus on 
the VM during late pregnancy. Interestingly, no changes in the 
bacterial counts of the most represented populations were revealed 
upon probiotic administration. However, the probiotic  mixture 
was able to change the composition of less  abundant  vaginal 
microorganisms by avoiding the reduction of Bifidobacterium and 
the increase of Atopobium recorded in the last trimester of preg-
nancy in control healthy women. Significant modifications of the 
local immune system were also associated with the consumption 
of the probiotic showing anti-inflammatory effects. In particular, 
vaginal levels of IL-4 and IL-10 were maintained in balance com-
pared to the reduction observed in control group. Furthermore, 
vaginal levels of eotaxin, a pro-inflammatory chemokine, were 
reduced upon probiotic dietary supplementation.
Lactoferrin
Similar to lactobacilli, also bLf exhibits effects on the host 
immune system, ranging from inhibition of inflammation to 
promotion of both innate and adaptive immune responses 
(108). Innate immunity is shaped by endogenous hLf through 
its interaction with PAMPs and/or pattern recognition receptors 
(PRRs) expressed by host cells. In vitro studies demonstrated 
that carbohydrate chains of hLf make it able to interact directly 
with TLR4 resulting in moderate activation of TLR4 associated 
pathways (109). LPS is a typical PAMP, which is bound by 
hLf, resulting in the inhibition of cell activation and inflam-
matory responses (110, 111). It has been proposed that in vivo 
hLf inhibits LPS-stimulated TLR4 signaling and depresses 
endotoxemia (112). In particular, upon LPS binding, hLf acts 
in reducing TNF-α, IL-1, and IL-6 production by immune cells 
(macrophages, neutrophils, and lymphocytes), as well as IL-8 
release by endothelial cells (113). It has been demonstrated that 
levels of hLf are increased in inflammatory diseases such as rheu-
matoid arthritis (114), severe acute respiratory syndrome (115), 
inflammatory bowel disease (116), and as mentioned above, some 
STD and BV (64). These observations suggest that hLf could be 
used as a clinical marker of inflammatory conditions. Besides 
PRRs and PAMPs binding, hLf displaces proteases from heparin 
in mast cells thus playing antiallergic effects (117). Furthermore, 
hLf competes with IL-8 through the binding to proteoglycans 
on endothelium, thus interfering with neutrophils recruitment 
to the site of inflammation (118). HLf has been shown to bind 
also DNA in the neutrophil extracellular traps (NETs), and this 
capability plays a key role in the context of NETosis, which is the 
NETs production by neutrophils. HLf adheres to the DNA struc-
tures released due to chromatin decondensation and spreading 
exerting its antimicrobial properties (119). In vitro experiments 
showed that recombinant hLf is able to induce maturation of 
antigen-presenting cells such as dendritic cells, thus suggesting 
that it can represent a link in shaping adaptive immunity (120). 
Depending on the external stimulus (pathogens, allergen, tumor 
antigens, etc.) and host immune status, hLf can modulate IL-4, 
IL-2, IL-12, or IFN-γ levels, thus providing different outcomes: 
strong Th1 polarization (infections, tumor), reduction of exces-
sive Th1 responses, and correction of Th1/Th2 balance (allergy, 
autoimmunity). Furthermore, Lf is able to support proliferation 
of T cell precursors and their differentiation. Besides its role in 
cellular-mediated immunity, hLf influences activation of B cells, 
thus playing a role also in humoral responses (113).
The effects of exogenous Lf on immune responses have been 
evaluated in different in  vitro systems. Different epithelial cell 
monolayers infected with various facultative or obligate intracel-
lular pathogens produce pro-inflammatory cytokines and the 
addition of bLf significantly decreased IL-1β, IL-6, IL-8, and 
NF-kB levels (84, 88, 121, 122). The results obtained in differ-
ent in vitro models and in various clinical trials confirm the bLf 
ability in downregulating pro-inflammatory cytokine synthesis. 
It has been demonstrated that exogenous bLf localizes into cell 
nucleus, thus acting as transcriptional factor and inhibiting 
pro-inflammatory cytokines (52, 122–124). Although the mecha-
nisms by which bLf exerts its anti-inflammatory activity are still 
under debate, recently, the bLf ability to decrease the high levels 
of IL-6 in CVF seems strictly related to its capacity to restore iron 
homeostasis disorders (52, 84). Therefore, Lf is not only a key ele-
ment in the host defense system (44, 125, 126) but also a pivotal 
component that is able to regulate the inflammatory response 
and iron homeostasis (52, 60–62). Recently, bLf is emerging 
as an attractive molecule for treating inflammation by ranging 
pro-inflammatory macrophagic phenotypes M1 to regulatory/
anti-inflammatory M2 phenotypes (90).
wOMeN LiFe: eSTROGeNS, 
LaCTObaCiLLi, aND Lf
Lactobacilli
Defenses of female mucosal genital tract are largely under the 
influence of hormones and paracrine production of various 
cytokines. Vaginal environment undergoes overtime shifts in the 
representation and abundance of microbial key species that are 
 influenced by factors that may include age, hormonal fluctuations, 
sexual activity, use of medication, and hygiene (12). The vagina is 
lined by stratified not keratinizing squamous epithelium, which is 
variable in thickness and structure depending on life stages. The 
vaginal epithelium consists of three cell layers: superficial, inter-
mediate, and basal capable of storing glycogen under the influence 
of estrogen. In the pre-pubertal and the postmenopausal women, 
the epithelium is thin and characterized by a basal layer of cells 
and several layers of parabasal cells. This thin atrophic epithelium 
is susceptible to infection and frequently shows degenerative and 
inflammatory changes. Vaginal epithelium reflects the hormonal 
changes of the menstrual cycle with increased mitosis of the basal 
layers. Under the influence of estrogen in the proliferative phase 
of the cycle, the whole epithelium thickens and is multilayered. 
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During the secretory phase of the cycle, the intermediate layers 
become thick and the cells stuffed with glycogen. Therefore, 
the glycogen content of the vaginal epithelium co-variates with 
estrogen levels. Breakdown of glycogen by resident healthy VM 
produces an acid pH in the vagina, which deters infections. Indeed, 
reproductive-age women carry Lactobacillus species (predominant 
lactic acid bacteria) and genera of Streptococcus and Atopobium, 
which conserved the ecological function of lactate production in 
the vaginal microbiome (127).
It is well demonstrated that fluctuations in the VM occur not 
only based on intercourse and infections but also during menstrual 
cycle. In general, high levels of estradiol may favor a lactobacilli-
dominant environment, especially L. crispatus, L. gasseri, and/or 
L. jensenii (128), which can be underrepresented in low estrogen 
conditions such as the beginning of a menstrual cycle or in post-
menopausal women. In one study, L. crispatus appears to decline 
during menses, while G. vaginalis increases along with L. iners 
and subsequently the concentration of both species decreases after 
menses (6). In other studies, L. crispatus has also been reported 
to decline 100-fold during menses, while the numbers of L. iners 
strongly increase (10, 11, 129).
Recently, cultivation-independent methods have highlighted 
the complexity and temporal variability of the VM (8, 130). In 
particular, Gajer et al. described temporal changes in the composi-
tion of VM in reproductive-age women within a 16-week period 
(129). In general, the highest variability of microbiota community 
was associated with menses. For example, a subject can show a 
community dominated by L. crispatus, which could be replaced by 
L. iners during menses or by Streptococcus spp. in a different subject. 
The same community could then revert to a community domi-
nated by L. crispatus at the end of menses. Moreover, the results 
also showed how some bacterial communities changed greatly 
over short time periods, while others were more stable. Hormone 
levels were combined with diversity data showing that an increase 
in estradiol and progesterone corresponded to decreased microbial 
variability. Vaginal metabolome data added information about 
community function, which was maintained despite changes in its 
composition. Indeed, shifts in community composition involved 
only changes in the relative dominance of a little number of differ-
ent bacteria that are able to produce lactic acid (129).
Interestingly, a recent study performed to investigate timing 
and sequence of changes that occur in the vaginal and vulvar 
microbiota during puberty showed that VM of perimenarcheal 
girls resembles those of reproductive-age women (131). In fact, 
L. crispatus, L. iners, L. gasseri, L. jensenii, and, in some subjects, 
Streptococcus spp. were dominant in the microbiota of girls before 
the onset of menarche in the early to middle stages of puberty. 
Further studies should be performed to increase knowledge 
about the link between estrogen, vaginal glycogen levels, lactic 
acid bacteria abundance, and vaginal pH.
Other important fluctuations in the vaginal microbiome 
are recorded during pregnancy. Aagaard et  al. showed that 
microbiome was enriched in L. iners, L. crispatus, L. jensenii, 
and L. johnsonii (132). The increase in lactobacilli may be due 
to the increase in estrogen levels that occurs during pregnancy 
although further investigations are needed to better under- 
stand the relationship between specific species of Lactobacillus and 
estrogen levels. However, another study shows that L. crispatus 
and L. iners dominate the vaginal flora as pregnancy progresses 
and maternal age seems to be important for the dominance of 
L. crispatus or L. iners, with L. iners being dominant in older 
gravidae (133).
As mentioned above, menopause usually represents a phase 
in which lactobacilli levels are low, but it seems that their implica-
tion is even more pronounced involving other features. Actually, 
inverse correlation has been found between Lactobacillus levels 
and vaginal dryness, a common condition of postmenopausal 
period, which was shown to be associated with changes in vaginal 
epithelial cell integrity and inflammation (134).
Besides the endogenous hormonal fluctuations, clinical evi-
dences demonstrate that the use of hormonal contraceptives is 
also able to induce changes in VM, thus influencing the sus-
ceptibility to STI and BV. Therefore, STI and BV (which in 
turn predisposes to STI) depend, in part, on modification of 
vaginal bacterial communities induced by some contraception 
methods. Clinical trials based on Nugent score endpoint and 
questionnaires have revealed a reduced BV rate in women who 
use estrogen-containing contraceptives (135, 136). The effects of 
progestin-containing contraceptives such as depot medroxypro-
gesterone acetate (DMPA) and levonorgestrel are less clear. In a 
systematic review of 36 eligible studies, authors have shown that 
combined oral contraceptives (COCs; combination of an estrogen 
and a progestin) and DMPA reduce BV by a range of 10–20 and 
18–30%, respectively (137). Accordingly, in a recent retrospective 
study on 682 fertile women, based on 16S rRNA sequencing, 
authors found that women using COC or DMPA showed a redu-
ced colonization by BV-associated bacteria compared to women 
using condoms. In the same study, women using progestin-
based therapies have a significantly higher abundance of taxa 
associated with a dysbiotic VM. On the other hand, COC users 
have a lactobacilli-dominated VM and a higher  proportion of 
H2O2-producing Lactobacillus species (L. crispatus, L.  gasseri, 
and L. jensenii) correlating with vaginal health compared to 
progestin-containing contraceptives (138) Differences in the 
results reported in other studies, which do not reveal any changes 
in vaginal bacterial communities associated with progestin use, 
could be due to the different study population characteristics 
(e.g., ethnicity of subjects) and/or the design of the study itself 
such as the specific BV status examination (139, 140). In women 
with BV, VM is not the only level that hormonal contraception 
acts on. In fact, changes in genital tract immunity by effect of 
hormonal contraceptives have been shown in terms of both sup-
pression and activation of responses. In a study on 81 women, 
cervical secretions contained lower levels of pro-inflammatory 
molecules (TNF, IFN-γ, and GM-CSF) in subjects with BV 
using hormonal contraceptives compared to those not using 
them (141). On the other hand, an increase of inflammatory 
cytokines (MIP-1α, MIP-1β, IL-6, IL-8, IP-10, and RANTES) 
has been associated with hormonal contraception in a different 
cross-sectional analysis including 376 African women (142). 
Conflicting data existing in these studies on immunomodula-
tory potential of hormonal contraception in female genital tract 
are complicated by their variability in terms of in  vitro versus 
in vivo models used and sample tested (plasma or blood versus 
 FiGURe 1 | Comparison among estrogen, progesterone, and Lactoferrin levels.
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cervical fluid). However, the investigation on these features may 
represent a key point in understanding the association between 
hormonal contraception and HIV acquisition. In fact, women 
using progestin DMPA, but not those who use COC have been 
found to be at significantly increased risk of HIV infection 
compared to women not using hormonal contraception (143). 
In a more recent case–control selection of specimens from a large, 
prospective, clinical study, the same authors have investigated on 
innate immunity mediators in cervical samples collected from 
199 women at their visit before HIV seroconversion and matched 
visits from 633 women remaining HIV uninfected. Higher levels 
of pro-inflammatory markers such as RANTES have been found 
in HIV seroconversion and in DMPA users, suggesting a possible 
role of this cytokine in the association between the contraceptive 
and HIV risk acquisition (144). The possible explanation could 
be that the upregulation of RANTES, observed in women using 
DMPA and women with BV, may simultaneously block the CCR5 
cellular HIV receptor but also facilitate transmission through 
recruiment of target cells. Also other STI can be influenced by 
hormonal contraception, such as candidiasis, which has been 
found increased in women using COC but not DMPA (137). Taken 
together, these observations suggest that altered immune responses 
by effect of hormonal contraception may predispose to infections 
from pathogens. In cases of a pre-existing condition of dysbiosis 
or specific cervicovaginal infection, suppression or activation of 
immunity by pathogens could increase the risk of infections by 
cumulative action with exogenous hormones.
Lactoferrin
Similar to the estrogen-induced changes in the species and 
number of lactobacilli, the hLf concentration fluctuates accord-
ingly to circulating estrogen levels (145–147). In addition to the 
hLf levels produced by uterine epithelium and released in CVF, 
the synthesis of IgA and IgG is also modulated by estrogen and 
progesterone, thus exerting an immune protection against sexu-
ally transmitted pathogens (148).
Figure 1 shows a comparison among estrogen, progesterone, 
and Lf levels during the proliferative, ovulatory, and secretory 
phase. The hLf levels increase in line with estrogen production, 
reaching the highest levels during ovulatory phase, while they 
are inversely correlated with progesterone levels. As a matter of 
fact, secretory phase accordingly to the increase of progester-
one shows the lowest levels of hLf. At the end of the secretory 
phase, hLf returns to increase in parallel to the progesterone 
decrease (145–149).
Obviously, the use of oral contraceptives by decreasing estrogen 
synthesis suppresses the production of hLf as well as immuno-
globulins for the duration of hormone exposure, thus possibly 
increasing the susceptibility of women to infections (148).
In rats, pretreatment with progesterone prior to exposure to 
Chlamydia thracomatis infection induced a persistent infection 
(150). Furthermore, the rats treated with progesterone were also 
found to be more vulnerable to chlamydial intrauterine infection, 
whereas the treatment with estradiol, the major female estrogen 
sex hormone, reduced the susceptibility to infection (151).
The sex steroid hormones are also important mediators of 
inflammation (152) and may influence resistance or susceptibil-
ity to parasitic infections (153). Sex steroid hormones are also 
involved in viral infections. It has been proposed that HIV-1 
utilizes a window of vulnerability during the menstrual cycle. 
This crucial period overlaps with the mid-cycle when innate and 
adaptive immune responses are suppressed by estrogens and/or 
progesterone to facilitate reproductive processes. HIV-1 presum-
ably exploits this time frame, during which antiviral factors are 
suppressed, to establish and propagate infection in the female 
mucosal genital tract (31, 148, 154). In menopausal women, the 
low concentration of hLf in the secretions, related to the low 
levels of sexual hormones (155), may lead to recurrent infections.
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It is important to underline that during menses the decrease 
of this important natural defense glycoprotein is balanced by the 
presence of neutrophils that, through the synthesis of granules, 
can restore, at least partially, hLf concentration and its anti-
microbial activity when the epithelial barrier is disrupted. The 
recruitment of neutrophils occurs through high levels of inflam-
matory biomarkers as pro-inflammatory cytokine as IL-8, IL-6 or 
C-reactive protein (119). As matter of fact, during menstruation, 
as well as in aging and menopause, the decrease of estrogens is 
related to the increase of inflammatory processes (156).
Interestingly, hLf expression in endometrium suggests that, 
during the gestational period, hLf produced by uterine epithe-
lium and neutrophils and released in CVF is controlled by sex 
steroid hormones (149). It has been reported that high levels 
of progesterone parallel low levels of estrogens in normal preg-
nancy, while this ratio is inverted in pregnant women with the 
preterm delivery threat (157). Determining the existence of a 
regulatory circuit linking hLF synthesis and sex steroid hormone 
fluctuations may unravel novel mechanisms leading to preterm 
birth.
FiGURe 2 | Lactobacillus spp. and lactoferrin interplay on infection and inflammation in female genital tract. A schematic representation of Lactobacillus spp.  
and lactoferrin balance: a multitasking strategy to protect against pathogen challenge and maintain immune homeostasis. (a) Healthy genital tract; (b) vaginosis: 
high levels of pro-inflammatory cytokines, decrease of lactobacilli and increase of Gram-negative anaerobes, and increase of lactoferrin concentration released by 
neutrophils; (C) decrease of pro-inflammatory cytokines by lactoferrin and restoration of healthy microbiota.
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CONCLUSiON
Lactobacillus spp. and Lf are pivotal components of first-line 
defense in the female mucosal genital tract involved in protection 
against a multitude of microbial infections and the most effective 
natural mechanism to dampen inflammatory processes.
To inhibit cervicovaginal infections, an ideal drug should 
inhibit:
•	 microbial growth;
•	 microbial adhesion and entry into host cells;
•	 microbial intracellular replication; and
•	 infection of new host cells by microbes extracellularly released 
from the infected cells.
In the vaginal environment of women of childbearing age, 
the inhibition of bacterial multiplication through the synthesis 
of antibacterial substances by lactobacilli or by competition 
between microbes and Lf for iron acquisition represents an 
effective natural defense mechanism. Both lactobacilli and Lf can 
inhibit the adhesion and consequently the microbial entry inside 
the cells through an interaction with the cell surface components 
potential receptors for pathogens. Lactobacilli and Lf appear 
 complementary since lactobacilli inhibit microbial intracellular 
replication and together with Lf hinder the infection of still healthy 
cells by microbes extracellularly released. This close cooperation 
is also exerted through their anti-inflammatory function. In this 
scenario, the mucosal environment represents a good model of 
mutualism and reciprocity against the injury by microbes.
A schematic representation of Lactobacillus spp. and Lf bal-
ance in protecting against pathogens and maintaining immune 
homeostasis in the vaginal tract is shown in Figure 2.
Considering the shortage of effective treatments to coun- 
teract antibiotic-resistant bacterial infections, the intravaginal 
administration of lactobacilli and Lf could be a novel efficient 
therapeutic strategy and a valuable tool to restore mucosal immune 
homeostasis.
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